Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales
As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in tumor microenvironment can be harnessed to battle cancer cells. In recent years, the administration of anti-CTLA or/and anti-PD-1/L1 antibody h...
Saved in:
| Published in | Cancer letters Vol. 456; pp. 23 - 28 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Ireland
Elsevier B.V
01.08.2019
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in tumor microenvironment can be harnessed to battle cancer cells. In recent years, the administration of anti-CTLA or/and anti-PD-1/L1 antibody has exhibited unexpected antitumor effect in multiple types of cancer, motivating the researchers to find more potential immune checkpoints as clinical targets. A wealth of clinical trials have been done to evaluate the safety and efficacy of monotherapy or combination therapy with immune checkpoint modulators. However, there still exist problems such as low response rate and adverse events in the clinical, which in turn leads us to the basic study. The better understanding of the crosstalk between the immune cells and the cancer cells within the microenvironment may inspire us new ideas for cancer treatment. In this review, we mainly summarize the recent advances in application of immune checkpoint modulators and the combination rationales, and discuss the problems existing in the precision therapy with immune checkpoint modulators.
•The application of anti-PD and anti-CTLA immune checkpoint modulators alone or in combination has exhibited unexpected antitumor effect in multiple types of cancer.•There are a lot of clinical studies of other checkpoint modulators, including the inhibitory modulators (LAG-3 inhibitor) and stimulatory modulators (agonists of CD27, OX-40, CD40, ICOS, 4-1BB and GITR), but their efficacy is still pending.•Despite the rapid progress in cancer immunotherapy, there still exist some problems to achieve precision therapy with immune checkpoint modulators. |
|---|---|
| AbstractList | As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in tumor microenvironment can be harnessed to battle cancer cells. In recent years, the administration of anti-CTLA or/and anti-PD-1/L1 antibody has exhibited unexpected antitumor effect in multiple types of cancer, motivating the researchers to find more potential immune checkpoints as clinical targets. A wealth of clinical trials have been done to evaluate the safety and efficacy of monotherapy or combination therapy with immune checkpoint modulators. However, there still exist problems such as low response rate and adverse events in the clinical, which in turn leads us to the basic study. The better understanding of the crosstalk between the immune cells and the cancer cells within the microenvironment may inspire us new ideas for cancer treatment. In this review, we mainly summarize the recent advances in application of immune checkpoint modulators and the combination rationales, and discuss the problems existing in the precision therapy with immune checkpoint modulators.
•The application of anti-PD and anti-CTLA immune checkpoint modulators alone or in combination has exhibited unexpected antitumor effect in multiple types of cancer.•There are a lot of clinical studies of other checkpoint modulators, including the inhibitory modulators (LAG-3 inhibitor) and stimulatory modulators (agonists of CD27, OX-40, CD40, ICOS, 4-1BB and GITR), but their efficacy is still pending.•Despite the rapid progress in cancer immunotherapy, there still exist some problems to achieve precision therapy with immune checkpoint modulators. As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in tumor microenvironment can be harnessed to battle cancer cells. In recent years, the administration of anti-CTLA or/and anti-PD-1/L1 antibody has exhibited unexpected antitumor effect in multiple types of cancer, motivating the researchers to find more potential immune checkpoints as clinical targets. A wealth of clinical trials have been done to evaluate the safety and efficacy of monotherapy or combination therapy with immune checkpoint modulators. However, there still exist problems such as low response rate and adverse events in the clinical, which in turn leads us to the basic study. The better understanding of the crosstalk between the immune cells and the cancer cells within the microenvironment may inspire us new ideas for cancer treatment. In this review, we mainly summarize the recent advances in application of immune checkpoint modulators and the combination rationales, and discuss the problems existing in the precision therapy with immune checkpoint modulators. As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in tumor microenvironment can be harnessed to battle cancer cells. In recent years, the administration of anti-CTLA or/and anti-PD-1/L1 antibody has exhibited unexpected antitumor effect in multiple types of cancer, motivating the researchers to find more potential immune checkpoints as clinical targets. A wealth of clinical trials have been done to evaluate the safety and efficacy of monotherapy or combination therapy with immune checkpoint modulators. However, there still exist problems such as low response rate and adverse events in the clinical, which in turn leads us to the basic study. The better understanding of the crosstalk between the immune cells and the cancer cells within the microenvironment may inspire us new ideas for cancer treatment. In this review, we mainly summarize the recent advances in application of immune checkpoint modulators and the combination rationales, and discuss the problems existing in the precision therapy with immune checkpoint modulators.As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in tumor microenvironment can be harnessed to battle cancer cells. In recent years, the administration of anti-CTLA or/and anti-PD-1/L1 antibody has exhibited unexpected antitumor effect in multiple types of cancer, motivating the researchers to find more potential immune checkpoints as clinical targets. A wealth of clinical trials have been done to evaluate the safety and efficacy of monotherapy or combination therapy with immune checkpoint modulators. However, there still exist problems such as low response rate and adverse events in the clinical, which in turn leads us to the basic study. The better understanding of the crosstalk between the immune cells and the cancer cells within the microenvironment may inspire us new ideas for cancer treatment. In this review, we mainly summarize the recent advances in application of immune checkpoint modulators and the combination rationales, and discuss the problems existing in the precision therapy with immune checkpoint modulators. |
| Author | Zheng, Yong-Fa Fan, Li Li, Yue Xu, Xi-Ming Chen, Jia-Yu |
| Author_xml | – sequence: 1 givenname: Li surname: Fan fullname: Fan, Li – sequence: 2 givenname: Yue surname: Li fullname: Li, Yue – sequence: 3 givenname: Jia-Yu surname: Chen fullname: Chen, Jia-Yu – sequence: 4 givenname: Yong-Fa surname: Zheng fullname: Zheng, Yong-Fa – sequence: 5 givenname: Xi-Ming surname: Xu fullname: Xu, Xi-Ming email: doctorxu120@aliyun.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30959079$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtr3DAUhUVJaSbT_oNSDN104-nVy49QCiUkbSBQKO1alaVrooktTSU7MP--cibZzGZWd6HvnHt1zgU588EjIe8pbCjQ6vN2Y7QfcNowoO0G-AYkvCIr2tSsrNsGzsgKOIiSN1yek4uUtgAgRS3fkHMOrWyhblfk7-04zh4Lc4_mYRecn4ox2HnQU4ipcL7ISwzGwi1YmO4x6t3-sviFBjOq7ePynArtbWHC2DmvJxd8EZ-GHjC9Ja97PSR89zzX5M_N9e-rH-Xdz--3V9_uSiMEn0rbiQ57YXsrdaOtta1soGNcUmwp66jWbUu1MdizWgiQrOF1Jau-p4YygYKvyaeD7y6GfzOmSY0uGRwG7THMSTEGFeO0znGsyccjdBvmmK9dKFbVUAngmfrwTM3diFbtoht13KuX7DJweQBMDClF7JVx09O_p6jdoCiopSi1VYei1FKUAq5yUVksjsQv_idkXw8yzFE-OowqGYe5AusimknZ4E4ZfDkyMIPzzujhAfen5f8B9frEAw |
| CitedBy_id | crossref_primary_10_1097_JCMA_0000000000000287 crossref_primary_10_1097_MD_0000000000030532 crossref_primary_10_3892_ol_2024_14849 crossref_primary_10_1016_j_apmt_2024_102341 crossref_primary_10_1186_s13046_020_01700_0 crossref_primary_10_1186_s12951_025_03229_w crossref_primary_10_3389_fcell_2021_686548 crossref_primary_10_1002_cam4_4221 crossref_primary_10_3389_fonc_2023_1200436 crossref_primary_10_1097_MD_0000000000034849 crossref_primary_10_1016_j_canlet_2020_03_024 crossref_primary_10_1016_j_phrs_2021_105735 crossref_primary_10_3390_cells9051181 crossref_primary_10_3389_fimmu_2020_01075 crossref_primary_10_1016_j_omtn_2022_08_021 crossref_primary_10_1016_j_nucmedbio_2020_05_006 crossref_primary_10_1016_S1470_2045_19_30461_9 crossref_primary_10_3389_fimmu_2020_621623 crossref_primary_10_3390_cancers12010057 crossref_primary_10_3389_fonc_2022_800291 crossref_primary_10_3389_fmolb_2021_598427 crossref_primary_10_1186_s12913_023_09736_6 |
| Cites_doi | 10.1006/smim.1998.0157 10.1200/JCO.2014.56.2736 10.1182/blood-2010-01-265975 10.1056/NEJMoa1200690 10.1200/jco.2013.31.15_suppl.3044 10.1038/s41591-018-0094-7 10.1093/intimm/10.4.453 10.1038/nri3108 10.4049/jimmunol.1300409 10.1056/NEJMoa1504030 10.1016/S0140-6736(17)31601-X 10.1158/1078-0432.CCR-14-2355 10.1002/j.1460-2075.1992.tb05481.x 10.1002/j.1460-2075.1992.tb05530.x 10.3389/fimmu.2018.02582 10.1016/j.ctrv.2015.11.001 10.1016/j.ejca.2015.11.016 10.1084/jem.180.2.631 10.1038/ncomms15081 10.1158/1078-0432.CCR-09-2033 10.1084/jem.192.7.1027 10.1200/jco.2013.31.15_suppl.9024 10.1016/j.cell.2018.09.035 10.1038/356607a0 10.1084/jem.20060210 10.1038/nm730 10.1038/415536a 10.1200/JCO.2016.70.1508 10.1186/s12929-017-0329-9 10.1093/annonc/mdx518 10.1038/35051100 10.1016/j.cell.2018.05.060 10.1016/S0140-6736(16)32517-X 10.1517/14728222.2014.980235 10.1038/ni987 10.1084/jem.173.3.721 10.1080/08916930500124072 10.1073/pnas.192461099 10.1111/imr.12520 10.1056/NEJMoa1200694 10.1016/S1470-2045(17)30446-1 10.1016/S0952-7915(99)80046-6 10.1016/S0065-2776(06)90008-X 10.1038/45582 10.1007/82_2017_62 10.1093/intimm/dxm057 10.1158/1078-0432.CCR-07-4079 10.3389/fimmu.2018.00385 10.1158/2326-6066.CIR-14-0118 10.1358/dot.2017.53.7.2654888 10.1016/j.ejca.2016.06.028 10.1016/j.cell.2018.11.010 10.1056/NEJMoa1003466 10.1111/imr.12518 10.1158/2326-6066.CIR-13-0086 10.1056/NEJMoa1809697 10.1038/nature25501 10.1126/science.271.5256.1734 10.1016/j.cell.2017.07.024 10.1016/S0140-6736(16)00561-4 10.2217/imt.15.32 10.1158/0008-5472.CAN-12-4174 10.1093/annonc/mdx755 10.1016/j.coi.2017.07.014 10.1136/esmoopen-2018-000375 10.1016/S1471-4906(02)02263-9 10.1242/dmm.029447 10.1016/j.cell.2017.01.017 10.1007/978-0-387-89520-8_10 10.1200/JCO.2012.44.6112 10.1073/pnas.0915174107 10.1146/annurev-med-092012-112807 10.1084/jem.182.2.459 10.1056/NEJMoa1709030 10.3389/fimmu.2018.01941 |
| ContentType | Journal Article |
| Copyright | 2019 Copyright © 2019. Published by Elsevier B.V. Copyright Elsevier Limited Aug 1, 2019 |
| Copyright_xml | – notice: 2019 – notice: Copyright © 2019. Published by Elsevier B.V. – notice: Copyright Elsevier Limited Aug 1, 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U9 H94 K9. NAPCQ 7X8 |
| DOI | 10.1016/j.canlet.2019.03.050 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1872-7980 |
| EndPage | 28 |
| ExternalDocumentID | 30959079 10_1016_j_canlet_2019_03_050 S0304383519302149 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29B 4.4 457 4CK 4G. 5GY 5RE 5VS 6J9 6PF 7-5 71M 8FE 8FH 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGSF ABJNI ABMAC ABMZM ABUDA ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IH2 IHE J1W K-O KOM LK8 M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSU SSZ T5K Z5R ~G- 7RV 7X7 8C1 8FI AACTN AAIAV ABLVK ABYKQ AFCTW AFKRA AFKWA AJOXV AMFUW AZQEC BBNVY BENPR BHPHI DOVZS EFLBG FYUFA GUQSH HCIFZ LCYCR M1P M2M M2O M7P RIG .55 .GJ 3O- 53G AAQXK AAYXX ABWVN ABXDB ACRPL ADMUD ADNMO AFFNX AFJKZ AGQPQ AGRDE AGRNS AI. AIGII ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HED HMK HMO HVGLF HZ~ R2- SAE SEW UDS VH1 WUQ X7M ZGI CGR CUY CVF ECM EIF NPM 7TO 7U9 H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c443t-db4bef4dfd5a8addd9580b2351e912b1aa991accef2744052837656ff1c124e43 |
| IEDL.DBID | .~1 |
| ISSN | 0304-3835 1872-7980 |
| IngestDate | Thu Jul 10 23:25:24 EDT 2025 Wed Aug 13 11:03:12 EDT 2025 Wed Feb 19 02:30:41 EST 2025 Tue Jul 01 02:29:39 EDT 2025 Thu Apr 24 23:12:24 EDT 2025 Fri Feb 23 02:33:48 EST 2024 Tue Aug 26 19:57:21 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Ani-PD-1/L1 Immune checkpoint modulators Combinational immunotherapy Anti-CTLA-4 |
| Language | English |
| License | Copyright © 2019. Published by Elsevier B.V. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c443t-db4bef4dfd5a8addd9580b2351e912b1aa991accef2744052837656ff1c124e43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| PMID | 30959079 |
| PQID | 2226706403 |
| PQPubID | 2031080 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2206231738 proquest_journals_2226706403 pubmed_primary_30959079 crossref_citationtrail_10_1016_j_canlet_2019_03_050 crossref_primary_10_1016_j_canlet_2019_03_050 elsevier_sciencedirect_doi_10_1016_j_canlet_2019_03_050 elsevier_clinicalkey_doi_10_1016_j_canlet_2019_03_050 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-08-01 |
| PublicationDateYYYYMMDD | 2019-08-01 |
| PublicationDate_xml | – month: 08 year: 2019 text: 2019-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland – name: Clare |
| PublicationTitle | Cancer letters |
| PublicationTitleAlternate | Cancer Lett |
| PublicationYear | 2019 |
| Publisher | Elsevier B.V Elsevier Limited |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier Limited |
| References | Krieg, Nowicka, Guglietta, Schindler, Hartmann, Weber, Dummer, Robinson, Levesque, Becher (bib71) 2018; 24 Kaleeba, Offner, Vandenbark, Lublinski, Weinberg (bib15) 1998; 10 Larkin, Chiarion-Sileni, Gonzalez, Grob, Cowey, Lao, Schadendorf, Dummer, Smylie, Rutkowski, Ferrucci, Hill, Wagstaff, Carlino, Haanen, Maio, Marquez-Rodas, McArthur, Ascierto, Long, Callahan, Postow, Grossmann, Sznol, Dreno, Bastholt, Yang, Rollin, Horak, Hodi, Wolchok (bib68) 2015; 373 Sanmamed, Chen (bib69) 2018; 175 LeBleu, Kalluri (bib77) 2018; 11 Infante, Powderly, Burris, Kittaneh, Grice, Smothers, Brett, Fleming, May, Marshall, Devenport, Pillemer, Pardoll, Chen, Langermann, LoRusso (bib46) 2013; 31 Siu, Even, Mesia, Remenar, Daste, Delord, Krauss, Saba, Nabell, Ready, Brana, Kotecki, Zandberg, Gilbert, Mehanna, Bonomi, Jarkowski, Melillo, Armstrong, Wildsmith, Fayette (bib54) 2018 Berger, Rotem-Yehudar, Slama, Landes, Kneller, Leiba, Koren-Michowitz, Shimoni, Nagler (bib47) 2008; 14 Watts, DeBenedette (bib10) 1999; 11 Kwon, Lee, Kwon (bib17) 2002; 23 He, Prostak, Thomas, Vitale, Weidlick, Crocker, Pilsmaker, Round, Tutt, Glennie, Marsh, Keler (bib59) 2013; 191 Pardoll (bib9) 2012; 12 Schachter, Ribas, Long, Arance, Grob, Mortier, Daud, Carlino, McNeil, Lotem, Larkin, Lorigan, Neyns, Blank, Petrella, Hamid, Zhou, Ebbinghaus, Ibrahim, Robert (bib58) 2017; 390 van de Ven, Borst (bib19) 2015; 7 Hodi, O'Day, McDermott, Weber, Sosman, Haanen, Gonzalez, Robert, Schadendorf, Hassel, Akerley, van den Eertwegh, Lutzky, Lorigan, Vaubel, Linette, Hogg, Ottensmeier, Lebbe, Peschel, Quirt, Clark, Wolchok, Weber, Tian, Yellin, Nichol, Hoos, Urba (bib35) 2010; 363 Dougall, Kurtulus, Smyth, Anderson (bib26) 2017; 276 Linsley, Brady, Grosmaire, Aruffo, Damle, Ledbetter (bib11) 1991; 173 Chen, Lee, Fisher, Jessen, Elliott, Evering, Logronio, Tu, Tsaparikos, Li, Wang, Ying, Xiong, VanArsdale, Lin (bib67) 2015; 3 Dong, Juedes, Temann, Shresta, Allison, Ruddle, Flavell (bib13) 2001; 409 Park, Omiya, Matsumura, Sakoda, Kuramasu, Augustine, Yao, Tsushima, Narazaki, Anand, Liu, Strome, Chen, Tamada (bib48) 2010; 116 Rittmeyer, Barlesi, Waterkamp, Park, Ciardiello, von Pawel, Gadgeel, Hida, Kowalski, Dols, Cortinovis, Leach, Polikoff, Barrios, Kabbinavar, Frontera, De Marinis, Turna, Lee, Ballinger, Kowanetz, He, Chen, Sandler, Gandara, Grp (bib51) 2017; 389 Iwai, Ishida, Tanaka, Okazaki, Honjo, Minato (bib6) 2002; 99 Petersone, Edner, Ovcinnikovs, Heuts, Ross, Ntavli, Wang, Walker (bib27) 2018; 9 Brahmer, Tykodi, Chow, Hwu, Topalian, Hwu, Drake, Camacho, Kauh, Odunsi, Pitot, Hamid, Bhatia, Martins, Eaton, Chen, Salay, Alaparthy, Grosso, Korman, Parker, Agrawal, Goldberg, Pardoll, Gupta, Wigginton (bib38) 2012; 366 Sharma, Hu-Lieskovan, Wargo, Ribas (bib72) 2017; 168 Topalian, Hodi, Brahmer, Gettinger, Smith, McDermott, Powderly, Carvajal, Sosman, Atkins, Leming, Spigel, Antonia, Horn, Drake, Pardoll, Chen, Sharfman, Anders, Taube, McMiller, Xu, Korman, Jure-Kunkel, Agrawal, McDonald, Kollia, Gupta, Wigginton, Sznol (bib39) 2012; 366 Iwai, Hamanishi, Chamoto, Honjo (bib22) 2017; 24 Wei, Levine, Cogdill, Zhao, Anang, Andrews, Sharma, Wang, Wargo, Pe'er, Allison (bib56) 2017; 170 Zhang, Slowikowski, Fonseka, Rao, Kelly, Goodman, Tabechian, Hughes, Salomon-Escoto, Watts, Apruzzese, Lieb, Mandelin, Boyle, Mandelin, Boyce, DiCarlo, Gravallese, Gregersen, Moreland, Firestein, Hacohen, Nusbaum, Lederer, Perlman, Pitzalis, Filer, Holers, Bykerk, Donlin, Anolik, Brenner, Raychaudhuri (bib75) 2018 Weber, Mandala, Del Vecchio, Gogas, Arance, Cowey, Dalle, Schenker, Chiarion-Sileni, Marquez-Rodas, Grob, Butler, Middleton, Maio, Atkinson, Queirolo, Gonzalez, Kudchadkar, Smylie, Meyer, Mortier, Atkins, Long, Bhatia, Lebbe, Rutkowski, Yokota, Yamazaki, Kim, de Pril, Sabater, Qureshi, Larkin, Ascierto, CheckMate (bib57) 2017; 377 Mariathasan, Turley, Nickles, Castiglioni, Yuen, Wang, Kadel, Koeppen, Astarita, Cubas, Jhunjhunwala, Banchereau, Yang, Guan, Chalouni, Ziai, Senbabaoglu, Santoro, Sheinson, Hung, Giltnane, Pierce, Mesh, Lianoglou, Riegler, Carano, Eriksson, Hoglund, Somarriba, Halligan, van der Heijden, Loriot, Rosenberg, Fong, Mellman, Chen, Green, Derleth, Fine, Hegde, Bourgon, Powles (bib76) 2018; 554 Hollenbaugh, Grosmaire, Kullas, Chalupny, Braesch-Andersen, Noelle, Stamenkovic, Ledbetter, Aruffo (bib21) 1992; 11 Strome, Dong, Tamura, Voss, Flies, Tamada, Salomao, Cheville, Hirano, Lin, Kasperbauer, Ballman, Chen (bib45) 2003; 63 Necchi, Joseph, Loriot, Hoffman-Censits, Perez-Gracia, Petrylak, Derleth, Tayama, Zhu, Ding, Kaiser, Rosenberg (bib49) 2017; 28 Lichtenegger, Rothe, Schnorfeil, Deiser, Krupka, Augsberger, Schluter, Neitz, Subklewe (bib66) 2018; 9 Chung, Eum, Lee, Lee, Lee, Kim, Ryu, Kim, Lee, Park, Kan, Han, Park (bib78) 2017; 8 Azizi, Carr, Plitas, Cornish, Konopacki, Prabhakaran, Nainys, Wu, Kiseliovas, Setty, Choi, Fromme, Dao, McKenney, Wasti, Kadaveru, Mazutis, Rudensky, Pe'er (bib79) 2018; 174 Leach, Krummel, Allison (bib1) 1996; 271 Cordes, Gulley (bib55) 2017; 53 Valdes-Mora, Handler, Law, Salomon, Oakes, Ormandy, Gallego-Ortega (bib80) 2018; 9 Knee, Hewes, Brogdon (bib18) 2016; 67 Okazaki, Wang (bib28) 2005; 38 Ware (bib20) 2009; 647 Schindler, Harmankaya, Postow, Frantal, Bello, Ariyan, Michielin, Hoeller, Pehamberger, Wolchok (bib36) 2013; 31 Antonia, Villegas, Daniel, Vicente, Murakami, Hui, Kurata, Chiappori, Lee, de Wit, Cho, Bourhaba, Quantin, Tokito, Mekhail, Planchard, Kim, Karapetis, Hiret, Ostoros, Kubota, Gray, Paz-Ares, Carpeno, Faivre-Finn, Reck, Vansteenkiste, Spigel, Wadsworth, Melillo, Taboada, Dennis, Ozguroglu, Investigators (bib53) 2018; 379 Rosenberg, Hoffman-Censits, Powles, van der Heijden, Balar, Necchi, Dawson, O'Donnell, Balmanoukian, Loriot, Srinivas, Retz, Grivas, Joseph, Galsky, Fleming, Petrylak, Perez-Gracia, Burris, Castellano, Canil, Bellmunt, Bajorin, Nickles, Bourgon, Frampton, Cui, Mariathasan, Abidoye, Fine, Dreicer (bib50) 2016; 387 Korman, Peggs, Allison (bib8) 2006; 90 Yoshinaga, Whoriskey, Khare, Sarmiento, Guo, Horan, Shih, Zhang, Coccia, Kohno, Tafuri-Bladt, Brankow, Campbell, Chang, Chiu, Dai, Duncan, Elliott, Hui, McCabe, Scully, Shahinian, Shaklee, Van, Mak, Senaldi (bib14) 1999; 402 Schaer, Budhu, Liu, Bryson, Malandro, Cohen, Zhong, Yang, Houghton, Merghoub, Wolchok (bib63) 2013; 1 Freeman, Long, Iwai, Bourque, Chernova, Nishimura, Fitz, Malenkovich, Okazaki, Byrne, Horton, Fouser, Carter, Ling, Bowman, Carreno, Collins, Wood, Honjo (bib5) 2000; 192 Krummel, Allison (bib2) 1995; 182 Fumet, Isambert, Hervieu, Zanetta, Guion, Hennequin, Rederstorff, Bertaut, Ghiringhelli (bib52) 2018; 3 Tang, Shalabi, Hubbard-Lucey (bib7) 2018; 29 Walker, Sansom (bib40) 2011; 11 Vinay, Kwon (bib16) 1998; 10 Muenst, Soysal, Tzankov, Hoeller (bib23) 2015; 19 Wang, Sanmamed, Datar, Su, Ji, Sun, Chen, Chen, Zhu, Yin, Zheng, Zhou, Badri, Yao, Zhu, Boto, Sznol, Melero, Vignali, Schalper, Chen (bib25) 2019; 176 Kirkwood, Lorigan, Hersey, Hauschild, Robert, McDermott, Marshall, Gomez-Navarro, Liang, Bulanhagui (bib41) 2010; 16 Harding, McArthur, Gross, Raulet, Allison (bib3) 1992; 356 Hathcock, Laszlo, Pucillo, Linsley, Hodes (bib12) 1994; 180 Joller, Kuchroo (bib30) 2017; 410 Koguchi, Anderson, Yang, O'Connor, Kuchroo, Hafler (bib32) 2006; 203 Das, Zhu, Kuchroo (bib24) 2017; 276 Michot, Bigenwald, Champiat, Collins, Carbonnel, Postel-Vinay, Berdelou, Varga, Bahleda, Hollebecque, Massard, Fuerea, Ribrag, Gazzah, Armand, Amellal, Angevin, Noel, Boutros, Mateus, Robert, Soria, Marabelle, Lambotte (bib73) 2016; 54 Sanchez-Fueyo, Tian, Picarella, Domenig, Zheng, Sabatos, Manlongat, Bender, Kamradt, Kuchroo, Gutierrez-Ramos, Coyle, Strom (bib29) 2003; 4 Schadendorf, Hodi, Robert, Weber, Margolin, Hamid, Patt, Chen, Berman, Wolchok (bib37) 2015; 33 Monney, Sabatos, Gaglia, Ryu, Waldner, Chernova, Manning, Greenfield, Coyle, Sobel, Freeman, Kuchroo (bib33) 2002; 415 Curran, Montalvo, Yagita, Allison (bib65) 2010; 107 Lo, Abdel-Motal (bib31) 2017; 49 Curti, Kovacsovics-Bankowski, Morris, Walker, Chisholm, Floyd, Walker, Gonzalez, Meeuwsen, Fox, Moudgil, Miller, Haley, Coffey, Fisher, Delanty-Miller, Rymarchyk, Kelly, Crocenzi, Bernstein, Sanborn, Urba, Weinberg (bib61) 2013; 73 Maio, Scherpereel, Calabro, Aerts, Perez, Bearz, Nackaerts, Fennell, Kowalski, Tsao, Taylor, Grosso, Antonia, Nowak, Taboada, Puglisi, Stockman, Kindler (bib43) 2017; 18 Ishida, Agata, Shibahara, Honjo (bib4) 1992; 11 Ribas, Kefford, Marshall, Punt, Haanen, Marmol, Garbe, Gogas, Schachter, Linette, Lorigan, Kendra, Maio, Trefzer, Smylie, McArthur, Dreno, Nathan, Mackiewicz, Kirkwood, Gomez-Navarro, Huang, Pavlov, Hauschild (bib42) 2013; 31 Okazaki, Honjo (bib34) 2007; 19 Dong, Strome, Salomao, Tamura, Hirano, Flies, Roche, Lu, Zhu, Tamada, Lennon, Celis, Chen (bib44) 2002; 8 Meng, Huang, Teng, Xing, Yu (bib70) 2015; 41 Burris, Infante, Ansell, Nemunaitis, Weiss, Villalobos, Sikic, Taylor, Northfelt, Carson, Hawthorne, Davis, Yellin, Keler, Bullock (bib60) 2017; 35 Johnson, Challis, Chowdhury, Gao, Harvey, Geldart, Kerr, Chan, Smith, Steven, Edwards, Ashton-Key, Hodges, Tutt, Ottensmeier, Glennie, Williams (bib62) 2015; 21 Page, Postow, Callahan, Allison, Wolchok (bib74) 2014; 65 Tran, Carvajal, Marabelle, Patel, LoRusso, Rasmussen, Juan, Upreti, Beers, Ngarmchamnanrith, Schoffski (bib64) 2018 Kirkwood (10.1016/j.canlet.2019.03.050_bib41) 2010; 16 Page (10.1016/j.canlet.2019.03.050_bib74) 2014; 65 Ribas (10.1016/j.canlet.2019.03.050_bib42) 2013; 31 Watts (10.1016/j.canlet.2019.03.050_bib10) 1999; 11 Ishida (10.1016/j.canlet.2019.03.050_bib4) 1992; 11 Korman (10.1016/j.canlet.2019.03.050_bib8) 2006; 90 Harding (10.1016/j.canlet.2019.03.050_bib3) 1992; 356 Lo (10.1016/j.canlet.2019.03.050_bib31) 2017; 49 Schachter (10.1016/j.canlet.2019.03.050_bib58) 2017; 390 Das (10.1016/j.canlet.2019.03.050_bib24) 2017; 276 Schaer (10.1016/j.canlet.2019.03.050_bib63) 2013; 1 Muenst (10.1016/j.canlet.2019.03.050_bib23) 2015; 19 Cordes (10.1016/j.canlet.2019.03.050_bib55) 2017; 53 Iwai (10.1016/j.canlet.2019.03.050_bib22) 2017; 24 Petersone (10.1016/j.canlet.2019.03.050_bib27) 2018; 9 Larkin (10.1016/j.canlet.2019.03.050_bib68) 2015; 373 Strome (10.1016/j.canlet.2019.03.050_bib45) 2003; 63 Maio (10.1016/j.canlet.2019.03.050_bib43) 2017; 18 Curti (10.1016/j.canlet.2019.03.050_bib61) 2013; 73 Tang (10.1016/j.canlet.2019.03.050_bib7) 2018; 29 Schadendorf (10.1016/j.canlet.2019.03.050_bib37) 2015; 33 Topalian (10.1016/j.canlet.2019.03.050_bib39) 2012; 366 Okazaki (10.1016/j.canlet.2019.03.050_bib34) 2007; 19 Berger (10.1016/j.canlet.2019.03.050_bib47) 2008; 14 Pardoll (10.1016/j.canlet.2019.03.050_bib9) 2012; 12 Sanchez-Fueyo (10.1016/j.canlet.2019.03.050_bib29) 2003; 4 LeBleu (10.1016/j.canlet.2019.03.050_bib77) 2018; 11 Wang (10.1016/j.canlet.2019.03.050_bib25) 2019; 176 Rittmeyer (10.1016/j.canlet.2019.03.050_bib51) 2017; 389 Hathcock (10.1016/j.canlet.2019.03.050_bib12) 1994; 180 Siu (10.1016/j.canlet.2019.03.050_bib54) 2018 Hodi (10.1016/j.canlet.2019.03.050_bib35) 2010; 363 Brahmer (10.1016/j.canlet.2019.03.050_bib38) 2012; 366 Chung (10.1016/j.canlet.2019.03.050_bib78) 2017; 8 Freeman (10.1016/j.canlet.2019.03.050_bib5) 2000; 192 Chen (10.1016/j.canlet.2019.03.050_bib67) 2015; 3 Leach (10.1016/j.canlet.2019.03.050_bib1) 1996; 271 Antonia (10.1016/j.canlet.2019.03.050_bib53) 2018; 379 Sanmamed (10.1016/j.canlet.2019.03.050_bib69) 2018; 175 Mariathasan (10.1016/j.canlet.2019.03.050_bib76) 2018; 554 Krummel (10.1016/j.canlet.2019.03.050_bib2) 1995; 182 Infante (10.1016/j.canlet.2019.03.050_bib46) 2013; 31 Dong (10.1016/j.canlet.2019.03.050_bib44) 2002; 8 Sharma (10.1016/j.canlet.2019.03.050_bib72) 2017; 168 Iwai (10.1016/j.canlet.2019.03.050_bib6) 2002; 99 Dong (10.1016/j.canlet.2019.03.050_bib13) 2001; 409 Monney (10.1016/j.canlet.2019.03.050_bib33) 2002; 415 Yoshinaga (10.1016/j.canlet.2019.03.050_bib14) 1999; 402 Kaleeba (10.1016/j.canlet.2019.03.050_bib15) 1998; 10 Dougall (10.1016/j.canlet.2019.03.050_bib26) 2017; 276 Kwon (10.1016/j.canlet.2019.03.050_bib17) 2002; 23 Park (10.1016/j.canlet.2019.03.050_bib48) 2010; 116 Necchi (10.1016/j.canlet.2019.03.050_bib49) 2017; 28 Weber (10.1016/j.canlet.2019.03.050_bib57) 2017; 377 Burris (10.1016/j.canlet.2019.03.050_bib60) 2017; 35 Ware (10.1016/j.canlet.2019.03.050_bib20) 2009; 647 He (10.1016/j.canlet.2019.03.050_bib59) 2013; 191 Krieg (10.1016/j.canlet.2019.03.050_bib71) 2018; 24 Hollenbaugh (10.1016/j.canlet.2019.03.050_bib21) 1992; 11 Koguchi (10.1016/j.canlet.2019.03.050_bib32) 2006; 203 Michot (10.1016/j.canlet.2019.03.050_bib73) 2016; 54 Linsley (10.1016/j.canlet.2019.03.050_bib11) 1991; 173 Zhang (10.1016/j.canlet.2019.03.050_bib75) 2018 Rosenberg (10.1016/j.canlet.2019.03.050_bib50) 2016; 387 Lichtenegger (10.1016/j.canlet.2019.03.050_bib66) 2018; 9 Curran (10.1016/j.canlet.2019.03.050_bib65) 2010; 107 Schindler (10.1016/j.canlet.2019.03.050_bib36) 2013; 31 Valdes-Mora (10.1016/j.canlet.2019.03.050_bib80) 2018; 9 Walker (10.1016/j.canlet.2019.03.050_bib40) 2011; 11 Azizi (10.1016/j.canlet.2019.03.050_bib79) 2018; 174 Johnson (10.1016/j.canlet.2019.03.050_bib62) 2015; 21 Joller (10.1016/j.canlet.2019.03.050_bib30) 2017; 410 Okazaki (10.1016/j.canlet.2019.03.050_bib28) 2005; 38 Vinay (10.1016/j.canlet.2019.03.050_bib16) 1998; 10 Wei (10.1016/j.canlet.2019.03.050_bib56) 2017; 170 Meng (10.1016/j.canlet.2019.03.050_bib70) 2015; 41 Tran (10.1016/j.canlet.2019.03.050_bib64) 2018 van de Ven (10.1016/j.canlet.2019.03.050_bib19) 2015; 7 Knee (10.1016/j.canlet.2019.03.050_bib18) 2016; 67 Fumet (10.1016/j.canlet.2019.03.050_bib52) 2018; 3 |
| References_xml | – volume: 38 start-page: 353 year: 2005 end-page: 357 ident: bib28 article-title: PD-1/PD-L pathway and autoimmunity publication-title: Autoimmunity – volume: 10 start-page: 453 year: 1998 end-page: 461 ident: bib15 article-title: The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells publication-title: Int. Immunol. – volume: 31 start-page: 616 year: 2013 end-page: 622 ident: bib42 article-title: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 11 start-page: 286 year: 1999 end-page: 293 ident: bib10 article-title: T cell co-stimulatory molecules other than CD28 publication-title: Curr. Opin. Immunol. – volume: 73 start-page: 7189 year: 2013 end-page: 7198 ident: bib61 article-title: OX40 is a potent immune-stimulating target in late-stage cancer patients publication-title: Cancer Res. – volume: 276 start-page: 97 year: 2017 end-page: 111 ident: bib24 article-title: Tim-3 and its role in regulating anti-tumor immunity publication-title: Immunol. Rev. – year: 2018 ident: bib54 article-title: Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial publication-title: JAMA Oncol – volume: 29 start-page: 84 year: 2018 end-page: 91 ident: bib7 article-title: Comprehensive analysis of the clinical immuno-oncology landscape publication-title: Ann. Oncol. : official journal of the European Society for Medical Oncology / ESMO – year: 2018 ident: bib75 article-title: Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by Integrating Single-Cell Transcriptomics and Mass Cytometry – volume: 276 start-page: 112 year: 2017 end-page: 120 ident: bib26 article-title: TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy publication-title: Immunol. Rev. – volume: 647 start-page: 146 year: 2009 end-page: 155 ident: bib20 article-title: Targeting the LIGHT-HVEM pathway publication-title: Therapeutic Targets of the Tnf Superfamily – volume: 373 start-page: 23 year: 2015 end-page: 34 ident: bib68 article-title: Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma publication-title: N. Engl. J. Med. – volume: 10 start-page: 481 year: 1998 end-page: 489 ident: bib16 article-title: Role of 4-1BB in immune responses publication-title: Semin. Immunol. – volume: 49 start-page: 14 year: 2017 end-page: 19 ident: bib31 article-title: Lessons from CTLA-4 deficiency and checkpoint inhibition publication-title: Curr. Opin. Immunol. – volume: 54 start-page: 139 year: 2016 end-page: 148 ident: bib73 article-title: Immune-related adverse events with immune checkpoint blockade: a comprehensive review publication-title: Eur. J. Cancer – volume: 23 start-page: 378 year: 2002 end-page: 380 ident: bib17 article-title: New insights into the role of 4-1BB in immune responses: beyond CD8(+) T cells publication-title: Trends Immunol. – volume: 21 start-page: 1321 year: 2015 end-page: 1328 ident: bib62 article-title: Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study publication-title: Clin. Cancer Res. : an official journal of the American Association for Cancer Research – volume: 3 start-page: 149 year: 2015 end-page: 160 ident: bib67 article-title: Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model publication-title: Cancer Immunol Res – volume: 11 start-page: 852 year: 2011 end-page: 863 ident: bib40 article-title: The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses publication-title: Nat. Rev. Immunol. – volume: 33 start-page: 1889 year: 2015 end-page: 1894 ident: bib37 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 415 start-page: 536 year: 2002 end-page: 541 ident: bib33 article-title: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease publication-title: Nature – volume: 9 year: 2018 ident: bib80 article-title: Single-cell transcriptomics in cancer immunobiology: the future of precision oncology publication-title: Front. Immunol. – volume: 8 year: 2017 ident: bib78 article-title: Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer publication-title: Nat. Commun. – volume: 90 start-page: 297 year: 2006 end-page: 339 ident: bib8 article-title: Checkpoint blockade in cancer immunotherapy publication-title: Adv. Immunol. – volume: 366 start-page: 2443 year: 2012 end-page: 2454 ident: bib39 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N. Engl. J. Med. – volume: 3 start-page: e000375 year: 2018 ident: bib52 article-title: Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer publication-title: ESMO Open – volume: 180 start-page: 631 year: 1994 end-page: 640 ident: bib12 article-title: Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function publication-title: J. Exp. Med. – volume: 31 year: 2013 ident: bib46 article-title: Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor publication-title: J. Clin. Oncol. – volume: 554 year: 2018 ident: bib76 article-title: TGF beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells publication-title: Nature – volume: 175 start-page: 313 year: 2018 end-page: 326 ident: bib69 article-title: A paradigm shift in cancer immunotherapy: from enhancement to normalization publication-title: Cell – volume: 18 start-page: 1261 year: 2017 end-page: 1273 ident: bib43 article-title: Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial publication-title: Lancet Oncol. – volume: 173 start-page: 721 year: 1991 end-page: 730 ident: bib11 article-title: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation publication-title: J. Exp. Med. – volume: 192 start-page: 1027 year: 2000 end-page: 1034 ident: bib5 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J. Exp. Med. – volume: 99 start-page: 12293 year: 2002 end-page: 12297 ident: bib6 article-title: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 182 start-page: 459 year: 1995 end-page: 465 ident: bib2 article-title: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation publication-title: J. Exp. Med. – volume: 11 start-page: 3887 year: 1992 end-page: 3895 ident: bib4 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J. – volume: 170 start-page: 1120 year: 2017 end-page: 1133 ident: bib56 article-title: Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade publication-title: Cell – volume: 271 start-page: 1734 year: 1996 end-page: 1736 ident: bib1 article-title: Enhancement of antitumor immunity by CTLA-4 blockade publication-title: Science – volume: 8 start-page: 793 year: 2002 end-page: 800 ident: bib44 article-title: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion publication-title: Nat. Med. – volume: 366 start-page: 2455 year: 2012 end-page: 2465 ident: bib38 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N. Engl. J. Med. – start-page: 6 year: 2018 ident: bib64 article-title: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors publication-title: J Immunother Cancer – volume: 19 start-page: 201 year: 2015 end-page: 211 ident: bib23 article-title: The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy publication-title: Expert Opin. Ther. Targets – volume: 7 start-page: 655 year: 2015 end-page: 667 ident: bib19 article-title: Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential publication-title: Immunotherapy-Uk – volume: 363 start-page: 711 year: 2010 end-page: 723 ident: bib35 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. – volume: 176 year: 2019 ident: bib25 article-title: Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3 publication-title: Cell – volume: 41 start-page: 868 year: 2015 end-page: 876 ident: bib70 article-title: Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy publication-title: Cancer Treat Rev. – volume: 24 start-page: 1773 year: 2018 end-page: 1775 ident: bib71 article-title: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy (vol 24, pg 144, 2018) publication-title: Nat. Med. – volume: 11 year: 2018 ident: bib77 article-title: A peek into cancer-associated fibroblasts: origins, functions and translational impact publication-title: Disease models & mechanisms – volume: 67 start-page: 1 year: 2016 end-page: 10 ident: bib18 article-title: Rationale for anti-GITR cancer immunotherapy publication-title: Eur. J. Cancer – volume: 31 year: 2013 ident: bib36 article-title: Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody publication-title: J. Clin. Oncol. – volume: 28 start-page: 3044 year: 2017 end-page: 3050 ident: bib49 article-title: Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study publication-title: Ann. Oncol. – volume: 191 start-page: 4174 year: 2013 end-page: 4183 ident: bib59 article-title: Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice publication-title: J. Immunol. – volume: 168 start-page: 707 year: 2017 end-page: 723 ident: bib72 article-title: Primary, adaptive, and acquired resistance to cancer immunotherapy publication-title: Cell – volume: 9 start-page: 385 year: 2018 ident: bib66 article-title: Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells publication-title: Front. Immunol. – volume: 402 start-page: 827 year: 1999 end-page: 832 ident: bib14 article-title: T-cell co-stimulation through B7RP-1 and ICOS publication-title: Nature – volume: 19 start-page: 813 year: 2007 end-page: 824 ident: bib34 article-title: PD-1 and PD-1 ligands: from discovery to clinical application publication-title: Int. Immunol. – volume: 24 year: 2017 ident: bib22 article-title: Cancer immunotherapies targeting the PD-1 signaling pathway publication-title: J. Biomed. Sci. – volume: 63 start-page: 6501 year: 2003 end-page: 6505 ident: bib45 article-title: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma publication-title: Cancer Res. – volume: 116 start-page: 1291 year: 2010 end-page: 1298 ident: bib48 article-title: B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance publication-title: Blood – volume: 16 start-page: 1042 year: 2010 end-page: 1048 ident: bib41 article-title: Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma publication-title: Clin. Cancer Res. : an official journal of the American Association for Cancer Research – volume: 356 start-page: 607 year: 1992 end-page: 609 ident: bib3 article-title: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones publication-title: Nature – volume: 9 start-page: 1941 year: 2018 ident: bib27 article-title: T cell/B cell collaboration and autoimmunity: an intimate relationship publication-title: Front. Immunol. – volume: 174 year: 2018 ident: bib79 article-title: Single-cell map of diverse immune phenotypes in the breast tumor microenvironment publication-title: Cell – volume: 377 start-page: 1824 year: 2017 end-page: 1835 ident: bib57 article-title: Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma publication-title: N. Engl. J. Med. – volume: 409 start-page: 97 year: 2001 end-page: 101 ident: bib13 article-title: ICOS co-stimulatory receptor is essential for T-cell activation and function publication-title: Nature – volume: 53 start-page: 377 year: 2017 end-page: 383 ident: bib55 article-title: Avelumab for the treatment of metastatic Merkel cell carcinoma publication-title: Drugs Today – volume: 1 start-page: 320 year: 2013 end-page: 331 ident: bib63 article-title: GITR pathway activation abrogates tumor immune suppression through loss of regulatory T-cell lineage stability publication-title: Cancer Immunology Research – volume: 389 start-page: 255 year: 2017 end-page: 265 ident: bib51 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet – volume: 379 start-page: 2342 year: 2018 end-page: 2350 ident: bib53 article-title: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC publication-title: N. Engl. J. Med. – volume: 35 start-page: 2028 year: 2017 end-page: 2036 ident: bib60 article-title: Safety and activity of Varlilumab, a novel and first-in-class Agonist anti-CD27 antibody, in patients with advanced solid tumors publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology – volume: 65 start-page: 185 year: 2014 end-page: 202 ident: bib74 article-title: Immune modulation in cancer with antibodies publication-title: Annu. Rev. Med. – volume: 410 start-page: 127 year: 2017 end-page: 156 ident: bib30 article-title: Tim-3, lag-3, and TIGIT publication-title: Curr Top Microbiol – volume: 387 start-page: 1909 year: 2016 end-page: 1920 ident: bib50 article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial publication-title: Lancet – volume: 4 start-page: 1093 year: 2003 end-page: 1101 ident: bib29 article-title: Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance publication-title: Nat. Immunol. – volume: 390 start-page: 1853 year: 2017 end-page: 1862 ident: bib58 article-title: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) publication-title: Lancet – volume: 12 start-page: 252 year: 2012 end-page: 264 ident: bib9 article-title: The blockade of immune checkpoints in cancer immunotherapy, Nature reviews publication-title: Cancer – volume: 107 start-page: 4275 year: 2010 end-page: 4280 ident: bib65 article-title: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 11 start-page: 4313 year: 1992 end-page: 4321 ident: bib21 article-title: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity publication-title: EMBO J. – volume: 203 start-page: 1413 year: 2006 end-page: 1418 ident: bib32 article-title: Dysregulated T cell expression of TIM3 in multiple sclerosis publication-title: J. Exp. Med. – volume: 14 start-page: 3044 year: 2008 end-page: 3051 ident: bib47 article-title: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies publication-title: Clin. Cancer Res. – volume: 10 start-page: 481 year: 1998 ident: 10.1016/j.canlet.2019.03.050_bib16 article-title: Role of 4-1BB in immune responses publication-title: Semin. Immunol. doi: 10.1006/smim.1998.0157 – volume: 33 start-page: 1889 year: 2015 ident: 10.1016/j.canlet.2019.03.050_bib37 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2014.56.2736 – volume: 116 start-page: 1291 year: 2010 ident: 10.1016/j.canlet.2019.03.050_bib48 article-title: B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance publication-title: Blood doi: 10.1182/blood-2010-01-265975 – volume: 366 start-page: 2443 year: 2012 ident: 10.1016/j.canlet.2019.03.050_bib39 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200690 – volume: 31 year: 2013 ident: 10.1016/j.canlet.2019.03.050_bib46 article-title: Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor publication-title: J. Clin. Oncol. doi: 10.1200/jco.2013.31.15_suppl.3044 – volume: 24 start-page: 1773 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib71 article-title: High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy (vol 24, pg 144, 2018) publication-title: Nat. Med. doi: 10.1038/s41591-018-0094-7 – volume: 10 start-page: 453 year: 1998 ident: 10.1016/j.canlet.2019.03.050_bib15 article-title: The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells publication-title: Int. Immunol. doi: 10.1093/intimm/10.4.453 – volume: 11 start-page: 852 year: 2011 ident: 10.1016/j.canlet.2019.03.050_bib40 article-title: The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3108 – volume: 191 start-page: 4174 year: 2013 ident: 10.1016/j.canlet.2019.03.050_bib59 article-title: Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice publication-title: J. Immunol. doi: 10.4049/jimmunol.1300409 – volume: 373 start-page: 23 year: 2015 ident: 10.1016/j.canlet.2019.03.050_bib68 article-title: Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504030 – volume: 390 start-page: 1853 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib58 article-title: Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) publication-title: Lancet doi: 10.1016/S0140-6736(17)31601-X – volume: 12 start-page: 252 year: 2012 ident: 10.1016/j.canlet.2019.03.050_bib9 article-title: The blockade of immune checkpoints in cancer immunotherapy, Nature reviews publication-title: Cancer – volume: 21 start-page: 1321 year: 2015 ident: 10.1016/j.canlet.2019.03.050_bib62 article-title: Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study publication-title: Clin. Cancer Res. : an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-14-2355 – volume: 11 start-page: 3887 year: 1992 ident: 10.1016/j.canlet.2019.03.050_bib4 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J. doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 11 start-page: 4313 year: 1992 ident: 10.1016/j.canlet.2019.03.050_bib21 article-title: The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity publication-title: EMBO J. doi: 10.1002/j.1460-2075.1992.tb05530.x – volume: 9 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib80 article-title: Single-cell transcriptomics in cancer immunobiology: the future of precision oncology publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.02582 – volume: 41 start-page: 868 year: 2015 ident: 10.1016/j.canlet.2019.03.050_bib70 article-title: Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2015.11.001 – volume: 54 start-page: 139 year: 2016 ident: 10.1016/j.canlet.2019.03.050_bib73 article-title: Immune-related adverse events with immune checkpoint blockade: a comprehensive review publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2015.11.016 – volume: 180 start-page: 631 year: 1994 ident: 10.1016/j.canlet.2019.03.050_bib12 article-title: Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function publication-title: J. Exp. Med. doi: 10.1084/jem.180.2.631 – volume: 8 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib78 article-title: Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer publication-title: Nat. Commun. doi: 10.1038/ncomms15081 – volume: 16 start-page: 1042 year: 2010 ident: 10.1016/j.canlet.2019.03.050_bib41 article-title: Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma publication-title: Clin. Cancer Res. : an official journal of the American Association for Cancer Research doi: 10.1158/1078-0432.CCR-09-2033 – volume: 192 start-page: 1027 year: 2000 ident: 10.1016/j.canlet.2019.03.050_bib5 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J. Exp. Med. doi: 10.1084/jem.192.7.1027 – volume: 31 year: 2013 ident: 10.1016/j.canlet.2019.03.050_bib36 article-title: Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody publication-title: J. Clin. Oncol. doi: 10.1200/jco.2013.31.15_suppl.9024 – volume: 175 start-page: 313 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib69 article-title: A paradigm shift in cancer immunotherapy: from enhancement to normalization publication-title: Cell doi: 10.1016/j.cell.2018.09.035 – volume: 356 start-page: 607 year: 1992 ident: 10.1016/j.canlet.2019.03.050_bib3 article-title: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones publication-title: Nature doi: 10.1038/356607a0 – volume: 203 start-page: 1413 year: 2006 ident: 10.1016/j.canlet.2019.03.050_bib32 article-title: Dysregulated T cell expression of TIM3 in multiple sclerosis publication-title: J. Exp. Med. doi: 10.1084/jem.20060210 – volume: 8 start-page: 793 year: 2002 ident: 10.1016/j.canlet.2019.03.050_bib44 article-title: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion publication-title: Nat. Med. doi: 10.1038/nm730 – volume: 415 start-page: 536 year: 2002 ident: 10.1016/j.canlet.2019.03.050_bib33 article-title: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease publication-title: Nature doi: 10.1038/415536a – volume: 35 start-page: 2028 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib60 article-title: Safety and activity of Varlilumab, a novel and first-in-class Agonist anti-CD27 antibody, in patients with advanced solid tumors publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2016.70.1508 – volume: 24 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib22 article-title: Cancer immunotherapies targeting the PD-1 signaling pathway publication-title: J. Biomed. Sci. doi: 10.1186/s12929-017-0329-9 – volume: 28 start-page: 3044 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib49 article-title: Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx518 – volume: 409 start-page: 97 year: 2001 ident: 10.1016/j.canlet.2019.03.050_bib13 article-title: ICOS co-stimulatory receptor is essential for T-cell activation and function publication-title: Nature doi: 10.1038/35051100 – volume: 174 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib79 article-title: Single-cell map of diverse immune phenotypes in the breast tumor microenvironment publication-title: Cell doi: 10.1016/j.cell.2018.05.060 – volume: 389 start-page: 255 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib51 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32517-X – volume: 19 start-page: 201 year: 2015 ident: 10.1016/j.canlet.2019.03.050_bib23 article-title: The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy publication-title: Expert Opin. Ther. Targets doi: 10.1517/14728222.2014.980235 – volume: 4 start-page: 1093 year: 2003 ident: 10.1016/j.canlet.2019.03.050_bib29 article-title: Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance publication-title: Nat. Immunol. doi: 10.1038/ni987 – volume: 173 start-page: 721 year: 1991 ident: 10.1016/j.canlet.2019.03.050_bib11 article-title: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation publication-title: J. Exp. Med. doi: 10.1084/jem.173.3.721 – volume: 38 start-page: 353 year: 2005 ident: 10.1016/j.canlet.2019.03.050_bib28 article-title: PD-1/PD-L pathway and autoimmunity publication-title: Autoimmunity doi: 10.1080/08916930500124072 – volume: 99 start-page: 12293 year: 2002 ident: 10.1016/j.canlet.2019.03.050_bib6 article-title: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.192461099 – volume: 276 start-page: 97 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib24 article-title: Tim-3 and its role in regulating anti-tumor immunity publication-title: Immunol. Rev. doi: 10.1111/imr.12520 – volume: 366 start-page: 2455 year: 2012 ident: 10.1016/j.canlet.2019.03.050_bib38 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200694 – volume: 18 start-page: 1261 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib43 article-title: Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(17)30446-1 – volume: 11 start-page: 286 year: 1999 ident: 10.1016/j.canlet.2019.03.050_bib10 article-title: T cell co-stimulatory molecules other than CD28 publication-title: Curr. Opin. Immunol. doi: 10.1016/S0952-7915(99)80046-6 – volume: 90 start-page: 297 year: 2006 ident: 10.1016/j.canlet.2019.03.050_bib8 article-title: Checkpoint blockade in cancer immunotherapy publication-title: Adv. Immunol. doi: 10.1016/S0065-2776(06)90008-X – volume: 402 start-page: 827 year: 1999 ident: 10.1016/j.canlet.2019.03.050_bib14 article-title: T-cell co-stimulation through B7RP-1 and ICOS publication-title: Nature doi: 10.1038/45582 – volume: 410 start-page: 127 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib30 article-title: Tim-3, lag-3, and TIGIT publication-title: Curr Top Microbiol doi: 10.1007/82_2017_62 – volume: 19 start-page: 813 year: 2007 ident: 10.1016/j.canlet.2019.03.050_bib34 article-title: PD-1 and PD-1 ligands: from discovery to clinical application publication-title: Int. Immunol. doi: 10.1093/intimm/dxm057 – volume: 14 start-page: 3044 year: 2008 ident: 10.1016/j.canlet.2019.03.050_bib47 article-title: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4079 – volume: 9 start-page: 385 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib66 article-title: Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.00385 – volume: 3 start-page: 149 year: 2015 ident: 10.1016/j.canlet.2019.03.050_bib67 article-title: Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0118 – volume: 53 start-page: 377 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib55 article-title: Avelumab for the treatment of metastatic Merkel cell carcinoma publication-title: Drugs Today doi: 10.1358/dot.2017.53.7.2654888 – volume: 67 start-page: 1 year: 2016 ident: 10.1016/j.canlet.2019.03.050_bib18 article-title: Rationale for anti-GITR cancer immunotherapy publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2016.06.028 – volume: 176 year: 2019 ident: 10.1016/j.canlet.2019.03.050_bib25 article-title: Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3 publication-title: Cell doi: 10.1016/j.cell.2018.11.010 – volume: 363 start-page: 711 year: 2010 ident: 10.1016/j.canlet.2019.03.050_bib35 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 276 start-page: 112 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib26 article-title: TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy publication-title: Immunol. Rev. doi: 10.1111/imr.12518 – volume: 1 start-page: 320 year: 2013 ident: 10.1016/j.canlet.2019.03.050_bib63 article-title: GITR pathway activation abrogates tumor immune suppression through loss of regulatory T-cell lineage stability publication-title: Cancer Immunology Research doi: 10.1158/2326-6066.CIR-13-0086 – volume: 379 start-page: 2342 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib53 article-title: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809697 – year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib75 – volume: 554 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib76 article-title: TGF beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells publication-title: Nature doi: 10.1038/nature25501 – volume: 271 start-page: 1734 year: 1996 ident: 10.1016/j.canlet.2019.03.050_bib1 article-title: Enhancement of antitumor immunity by CTLA-4 blockade publication-title: Science doi: 10.1126/science.271.5256.1734 – volume: 170 start-page: 1120 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib56 article-title: Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade publication-title: Cell doi: 10.1016/j.cell.2017.07.024 – volume: 63 start-page: 6501 year: 2003 ident: 10.1016/j.canlet.2019.03.050_bib45 article-title: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma publication-title: Cancer Res. – volume: 387 start-page: 1909 year: 2016 ident: 10.1016/j.canlet.2019.03.050_bib50 article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)00561-4 – volume: 7 start-page: 655 year: 2015 ident: 10.1016/j.canlet.2019.03.050_bib19 article-title: Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential publication-title: Immunotherapy-Uk doi: 10.2217/imt.15.32 – volume: 73 start-page: 7189 year: 2013 ident: 10.1016/j.canlet.2019.03.050_bib61 article-title: OX40 is a potent immune-stimulating target in late-stage cancer patients publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-4174 – volume: 29 start-page: 84 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib7 article-title: Comprehensive analysis of the clinical immuno-oncology landscape publication-title: Ann. Oncol. : official journal of the European Society for Medical Oncology / ESMO doi: 10.1093/annonc/mdx755 – volume: 49 start-page: 14 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib31 article-title: Lessons from CTLA-4 deficiency and checkpoint inhibition publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2017.07.014 – volume: 3 start-page: e000375 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib52 article-title: Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer publication-title: ESMO Open doi: 10.1136/esmoopen-2018-000375 – start-page: 6 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib64 article-title: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid- induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors publication-title: J Immunother Cancer – volume: 23 start-page: 378 year: 2002 ident: 10.1016/j.canlet.2019.03.050_bib17 article-title: New insights into the role of 4-1BB in immune responses: beyond CD8(+) T cells publication-title: Trends Immunol. doi: 10.1016/S1471-4906(02)02263-9 – volume: 11 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib77 article-title: A peek into cancer-associated fibroblasts: origins, functions and translational impact publication-title: Disease models & mechanisms doi: 10.1242/dmm.029447 – volume: 168 start-page: 707 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib72 article-title: Primary, adaptive, and acquired resistance to cancer immunotherapy publication-title: Cell doi: 10.1016/j.cell.2017.01.017 – volume: 647 start-page: 146 year: 2009 ident: 10.1016/j.canlet.2019.03.050_bib20 article-title: Targeting the LIGHT-HVEM pathway publication-title: Therapeutic Targets of the Tnf Superfamily doi: 10.1007/978-0-387-89520-8_10 – volume: 31 start-page: 616 year: 2013 ident: 10.1016/j.canlet.2019.03.050_bib42 article-title: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma publication-title: J. Clin. Oncol. : official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2012.44.6112 – volume: 107 start-page: 4275 year: 2010 ident: 10.1016/j.canlet.2019.03.050_bib65 article-title: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0915174107 – volume: 65 start-page: 185 year: 2014 ident: 10.1016/j.canlet.2019.03.050_bib74 article-title: Immune modulation in cancer with antibodies publication-title: Annu. Rev. Med. doi: 10.1146/annurev-med-092012-112807 – volume: 182 start-page: 459 year: 1995 ident: 10.1016/j.canlet.2019.03.050_bib2 article-title: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation publication-title: J. Exp. Med. doi: 10.1084/jem.182.2.459 – year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib54 article-title: Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial publication-title: JAMA Oncol – volume: 377 start-page: 1824 year: 2017 ident: 10.1016/j.canlet.2019.03.050_bib57 article-title: Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709030 – volume: 9 start-page: 1941 year: 2018 ident: 10.1016/j.canlet.2019.03.050_bib27 article-title: T cell/B cell collaboration and autoimmunity: an intimate relationship publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.01941 |
| SSID | ssj0005475 |
| Score | 2.4137163 |
| SecondaryResourceType | review_article |
| Snippet | As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 23 |
| SubjectTerms | Ani-PD-1/L1 Animals Anti-CTLA-4 Antigens Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antitumor activity Apoptosis Autoimmune diseases Biomarkers Cancer Cancer immunotherapy Carcinogenesis Cell Communication Clinical trials Combinational immunotherapy Editing Fibroblasts Homeostasis Humans Immune checkpoint Immune checkpoint modulators Immunoglobulins Immunomodulation Immunosurveillance Immunotherapy Ligands Lymphocytes Melanoma Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Neoplasms - pathology PD-1 protein Proteins Response rates Signal Transduction Treatment Outcome Tumor Microenvironment Tumor necrosis factor-TNF |
| Title | Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0304383519302149 https://dx.doi.org/10.1016/j.canlet.2019.03.050 https://www.ncbi.nlm.nih.gov/pubmed/30959079 https://www.proquest.com/docview/2226706403 https://www.proquest.com/docview/2206231738 |
| Volume | 456 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB5VrIS4IJZnWbYyElfTJnbqdG8ILSoguAASN5P4IYVHUrXlwIXfvjOJU4G0CMQxyYzkzNgznz0PAxz42Hsb2ZSL1OZcKjnkaeoNN7ERRtrUy_r2hovL4fhGnt0mtx04bmthKK0y2P7GptfWOrzpB2n2J0XRv6KgHu6vCIJQ4y8q4pNS0Sw_fH2T5iHrZrtEzIm6LZ-rc7xw9CgdSvBqWp1S9f3_3dNH8LN2QydrsBrwIztqhvgTOq5ch-WLECHfgLtTKvhwDHVhHiZVUc7ZU2Xpjq5qOmNFyQypecoKIgvVVy9_GKJH9D4sZATMWFZahiLBbXOtOTYNZ4Zutgk3J3-vj8c83KLAjZRizm0uc-el9TbJUrRmdpSkgzxGublRFOdRliFEzIxxvm4WSM1eFII87yODvt9JsQVLZVW6HWDOR7lRtAND0Gikyn1ipItG0iFsiI3vgmiFp01oMU43XTzqNpfsXjci1yRyPRAaRd4FvuCaNC02PqFPWr3otnwUDZ5GH_AJn1rwvZtiX-Dca9WvwxKfaQRWQ0VxUNGF_cVnXJwUcclKVz0TzQDhZaRE2oXtZtosflHQCexAjXa_PaxfsEJPTTriHizNp8_uN0Kked6r10APfhydno8v_wHqMBGR |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB61RWp7QdAWurBQI9Gj2U3sbBIkDgiodttuL22l3tzEDyk8ktVmK7QX_hR_kJnEWRUJVITUa_yQMzOe-WzPA-C1C50zgUm4SEzOZSxHPEmc5jrUQkuTONlUb5iejcaX8vgqulqDn10sDLlVet3f6vRGW_svA0_NwawoBuf0qIfnK4IglPgr9Z6VJ3b5Hc9t9bvJR2TyYRgefbr4MOa-tADXUooFN7nMrZPGmShLcIubNEqGeYiT2TQI8yDLEDdlWlvXZNCjDCgxIh_nAo0G0UqB867DA4nqgsomvPlxy69ENtl9aXWcltfF6zVOZUguZAd5lLW5VSnc_8_28G94t7F7R4_goQes7H1Lk8ewZssd2Jz6J_lduJ5QhIllyHz9ZVYV5YJ9qwwVBavmNStKpkmu5qygbj7ca_mWIVxFc8e8C0LNstIw5AGe0xtRYXN_SWnrPbi8F9o-gY2yKu0-MOuCXMd05EOUqmWcu0hLG6TSIk4JteuB6IintM9pTqU1vqrOee2zakmuiORqKBSSvAd8NWrW5vS4o3_U8UV18aqoYRUanTvGxatxv8n0P4zsd-xXXqfUCpHcKKaHV9GDV6tm1Ab0xJOVtrqhPkPEs0Eskh48bcVm9YuCrnyHcfrsv5d1AFvji-mpOp2cnTyHbWppfSH7sLGY39gXiM8W-ctmPzCUv3vegL8AGmNOBQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immune+checkpoint+modulators+in+cancer+immunotherapy%3A+Recent+advances+and+combination+rationales&rft.jtitle=Cancer+letters&rft.au=Fan%2C+Li&rft.au=Li%2C+Yue&rft.au=Chen%2C+Jia-Yu&rft.au=Zheng%2C+Yong-Fa&rft.date=2019-08-01&rft.issn=1872-7980&rft.eissn=1872-7980&rft.volume=456&rft.spage=23&rft_id=info:doi/10.1016%2Fj.canlet.2019.03.050&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-3835&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-3835&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-3835&client=summon |